^
Association details:
| Biomarker: | EGFR exon 21 deletion |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Mekinist (trametinib) (MEK inhibitor) + Tagrisso (osimertinib) (EGFR inhibitor) + Tafinlar (dabrafenib) (BRAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Promising response of dabrafenib, trametinib, and osimertinib combination therapy for concomitant BRAF and EGFR-TKI resistance mutations
Published date:
08/14/2023
Excerpt:
A biopsy confirmed the presence of lung adenocarcinoma....Further examination through a lymph node biopsy revealed an EGFR exon 21 deletion, with an ECOG score of 2....To address this, a combined treatment involving osimertinib, dabrafenib, and trametinib was administered, resulting in a significant reduction in liver and pancreatic metastases and notable improvement in symptoms, with an ECOG score of 1. Adverse events were manageable. At the last follow-up in June 2023, the patient’s disease assessment still indicated a maintenance of partial remission.
DOI:
10.1097/CAD.0000000000001537
